FEHB GLP 1 coverage for weight loss will require behavioral therapy in 2027
OPM will require every FEHB and postal health plan to tie GLP 1 weight loss drugs to an intensive behavioral therapy program in 2027, and most carriers are raising the member cost share to 50%.
What's new
From 2027 every FEHB and PSHB carrier will require documented intensive behavioral therapy before and during treatment with anti obesity medications, and most carriers are raising the GLP 1 cost share to 50%.
Why it matters
GLP 1 spending at two large FEHB carriers grew more than 500% from 2019 to 2024, and members on weight loss drugs now face a new prior authorization step.
What's next
Open season runs to 14 December 2026, and carriers will apply the therapy rule from the new plan year in January.
FEHB GLP 1 coverage for weight loss comes with a new condition in 2027. Every plan in the Federal Employees Health Benefits program will require members to take part in an intensive behavioral therapy program before and during treatment with anti obesity medications, the Office of Personnel Management said in its open season materials. A Federal News Network column published on 16 November adds that most carriers will also raise the member share of GLP 1 drug costs to 50%.
What OPM changed for anti obesity medications
The rule sits in OPM's open season highlights for the 2027 plan year. Plans must keep covering at least one GLP 1 anti obesity medication and at least two oral anti obesity medications, as in earlier years. What is new is the gate placed in front of FEHB GLP 1 coverage. All carriers in the FEHB program and in the Postal Service Health Benefits program will require documented participation in an evidence based intensive behavioral therapy program, both before a member starts a weight loss drug and while they stay on it. Plans are expected to pay for individual and group therapy and for medical nutrition therapy, including between 12 and 22 therapy sessions a year depending on progress, according to the OPM 2027 open season highlights.
OPM also set a floor for what counts as a qualifying program. It must offer 26 or more contact hours over three to twelve months and must track and report participation, completion, weight change and specified cardiometabolic outcomes. Plans must also cover such programs for children and teenagers aged six and older whose body mass index is above the 95th percentile, and carriers have to line up the therapy rules with their existing criteria for medicines and metabolic surgery. Open season runs from 9 November to 14 December 2026, and the changes apply from the new plan year in January. The FEHB program, which includes the postal plans, covers about 7.9 million employees, annuitants and family members, according to OPM.
Why FEHB GLP 1 coverage is getting stricter
Cost is the driver OPM names. Its highlights list higher prescription drug spending, particularly on GLP 1 drugs, specialty drugs and other high cost therapies, among the main reasons premiums are rising. For 2027 the average FEHB premium goes up 9.3%, and the average enrollee share rises 10.9%. An OPM Office of Inspector General data brief, cited in the column, studied the two carriers that together cover 69% of FEHB members. At those two carriers, GLP 1 spending grew more than 500% in five years, from about $392 million in 2019 to $2.6 billion in 2024. The brief looked only at those two carriers, so it does not give a total for the whole program.
At those two carriers, GLP 1 spending grew more than 500% in five years, from about $392 million in 2019 to $2.6 billion in 2024.
The column was written by Kevin Moss, a senior editor at Consumers' Checkbook, for the Federal News Network benefits section. He wrote that most carriers are moving to a 50% member cost share for GLP 1 drugs. Figures taken from carrier pricing tools showed wide gaps between plans, he reported. In SAMBA High, a nationwide plan, the member cost for Wegovy rises about 500% and for Zepbound more than 400% against this year, while in Compass Rose High the rise is about 13%. These are the column's own checks of a few plans, not an OPM figure, and members will see different amounts by plan. The pattern echoes employer GLP 1 coverage trends across private jobs.
Intensive behavioral therapy and who must take it
The therapy requirement applies when a GLP 1 drug is prescribed for weight loss. Members who take the same class of drugs for type 2 diabetes or for severe sleep apnea should not have to complete the program, according to the column, which advises current users to ask their plan whether the new prior authorization applies to them. Carriers are working with outside vendors to run the sessions, which the column describes as virtual and free to members. OPM's summary does not say whether a human coach is required or what happens to members who miss sessions, and those details will sit in each plan brochure. Because OPM requires participation during treatment, the rule reaches people already on a drug, not only new starters.
Federal retirees who are also in Medicare face a different calculation. The column notes that Medicare Part D coverage tied to an FEHB plan often charges far less for GLP 1 drugs than the plan's own drug benefit. It also points to the Medicare GLP 1 Bridge, a temporary Medicare program that runs from 1 July 2026 through 31 December 2027 and covers Wegovy, the Zepbound KwikPen and Foundayo for weight loss. The Obesity Action Coalition says enrollees need Part D or a Medicare Advantage drug plan, a prescription and a qualifying body mass index. Coverage for low income groups has moved the other way, as GLP 1 Medicaid coverage narrows in several states. The table below sorts the main changes by source.
| Item | 2027 rule or figure | Source |
|---|---|---|
| Behavioral therapy | Required before and during anti obesity drug treatment | OPM |
| Therapy sessions covered | 12 to 22 a year depending on progress | OPM |
| Qualifying program | 26 or more contact hours over 3 to 12 months | OPM |
| Drug coverage floor | At least one GLP 1 and two oral anti obesity drugs | OPM |
| Member cost share | 50% at most carriers | Federal News Network column |
| Open season | 9 November to 14 December 2026 | OPM |
What comes next for federal enrollees
Members have until 14 December to change plans, and OPM says full plan brochures and a comparison tool are on its website. Anyone now on a GLP 1 drug for weight loss will need to check how their carrier applies the therapy rule in January, how long approval takes and whether sessions already completed count. The column also notes that payments made outside the plan do not count toward the plan deductible or the catastrophic limit, which matters for members with high medical costs. Those trade offs differ by plan, family size and health status, so no single route suits everyone, and any change in treatment should be discussed with the prescriber who manages it.
The wider question is whether the therapy gate improves results or mainly lowers use. OPM has asked qualifying programs to report weight change and cardiometabolic outcomes, which could give the agency evidence on that point if it publishes the data. The labels of these drugs already describe them as an addition to a reduced calorie diet and more physical activity, but tying access to documented attendance adds paperwork for members and prescribers. How many members drop off during prior authorization, and whether spending growth slows, will only show up in later reports. Other coverage decisions on peptide medicines are followed on the Peptide Zone regulators desk, including moves driven by the same cost pressure.
Conclusion
FEHB GLP 1 coverage for weight loss stays in place for 2027, but it now depends on documented behavioral therapy before and during treatment, and at most carriers on a larger member share of the cost. OPM ties the change to fast rising drug spending. Members on these drugs should read their 2027 plan brochure and ask their carrier how the new prior authorization will work before open season closes on 14 December.